A randomised controlled trial to compare the incidence of bleeding events following prophylactic versus no prophylactic platelet transfusions in patients with haematological malignancies

ational Health Service Blood & Transplant0 个研究点目标入组 600 人开始时间: 2009年12月18日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Patients are eligible for this trial if:
•1. They are aged 16 years or over
•2. They have a confirmed diagnosis of a haematological malignancy
•3. They have received or are going to receive myelosuppressive chemotherapy on this hospital admission with or without haematopoietic stem cell support (this includes patients undergoing haematopoietic stem cell transplantation - autologous or allogeneic)
•4. They are thrombocytopenic or expected to become thrombocytopenic with a platelet count of less than 50 x 10e9/L for at least 5 days
•5. They are able to comply with treatment and monitoring

•Patients are not eligible for this trial if:
•1. They have had a WHO Grade 3 or 4 bleed during any stage of their treatment to date
•2. During the current admission, they have experienced or are currently experiencing a WHO Grade 2 or greater bleed
•3. They have any inherited clotting disorder (e.g. haemophilia)
•4. They need to remain on regular aspirin (or related drugs), or will require therapeutic doses of anticoagulants (e.g. heparin), during the whole period of thrombocytopenia
•5. They have acute promyelocytic leukaemia and undergoing induction chemotherapy
•6. They have known human leukocyte antigen (HLA) antibodies
•7. They are pregnant
•8. They have previously been randomised in this trial at any stage of their treatment

发起方

ational Health Service Blood & Transplant